Hikma Pharmaceuticals
Company Details
Linkedin ID:
hikma-pharmaceuticals
Website:
Employees number:
10,252
Number of followers:
637,630
NAICS:
3254
Industry Type:
Homepage:
hikma.com
IP Addresses:
31
Company ID:
HIK_2329616
Scan Status:
Completed
Internal validation & live display
Multiple badges & continuous verification
Faster underwriting decisions
Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score
hikma.comFor almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Hikma Pharmaceuticals A.I CyberSecurity Scoring
Hikma Pharmaceuticals Risk Score (AI oriented)Between 750 and 799
Hikma Pharmaceuticals
Updated:
- Powered by our proprietary A.I cyber incident model
- Insurance preferes TPRM score to calculate premium
Hikma Pharmaceuticals Global Score (TPRM)XXXX
Hikma Pharmaceuticals
- Instant access to detailed risk factors
- Benchmark vs. industry & size peers
- Vulnerabilities
- Findings
Hikma Pharmaceuticals Company CyberSecurity News & History
Past Incidents
0
Attack Types
0
No data available
Hikma Pharmaceuticals Company Scoring based on AI Models
Cyber Incidents Likelihood 3 - 6 - 9 months
A.I Risk Score Likelihood 3 - 6 - 9 months
Underwriter Stats for Hikma Pharmaceuticals
Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2026.
Incidents vs All-Companies Average (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2026.
Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2026.
Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)
Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries
Hikma Pharmaceuticals Company Subsidiaries
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Loading...
Hikma Pharmaceuticals Similar Companies
Parexel
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldw
Cipla
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purp
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (C
Intas Pharmaceuticals
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Acc
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine
Lonza
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Sw
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions i
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating wit
.png)
Hikma Pharmaceuticals CyberSecurity News
March 05, 2026 08:00 AM
How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge
Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...
February 26, 2026 08:00 AM
Hikma Pharma's gloomy outlook kicks shares to more than three-year low
British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...
February 06, 2026 08:00 AM
What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)
The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...
January 08, 2026 08:00 AM
Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value
Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...
December 16, 2025 08:00 AM
The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses
Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.
December 15, 2025 08:00 AM
How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves
Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...
November 28, 2025 08:00 AM
How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation
Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.
November 13, 2025 08:00 AM
Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates
Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...
September 19, 2025 07:00 AM
Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company
Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
Hikma Pharmaceuticals CyberSecurity History Information
Official Website of Hikma Pharmaceuticals
The official website of Hikma Pharmaceuticals is http://www.hikma.com.
Hikma Pharmaceuticals’s AI-Generated Cybersecurity Score
According to Rankiteo, Hikma Pharmaceuticals’s AI-generated cybersecurity score is 767, reflecting their Fair security posture.
How many security badges does Hikma Pharmaceuticals’ have ?
According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?
According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.
Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?
According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.
Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?
According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.
Does Hikma Pharmaceuticals comply with GDPR ?
According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.
Does Hikma Pharmaceuticals have PCI DSS certification ?
According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.
Does Hikma Pharmaceuticals comply with HIPAA ?
According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.
Does Hikma Pharmaceuticals have ISO 27001 certification ?
According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Industry Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.
Number of Employees at Hikma Pharmaceuticals
Hikma Pharmaceuticals employs approximately 10,252 people worldwide.
Subsidiaries Owned by Hikma Pharmaceuticals
Hikma Pharmaceuticals presently has no subsidiaries across any sectors.
Hikma Pharmaceuticals’s LinkedIn Followers
Hikma Pharmaceuticals’s official LinkedIn profile has approximately 637,630 followers.
NAICS Classification of Hikma Pharmaceuticals
Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Hikma Pharmaceuticals’s Presence on Crunchbase
Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.
Hikma Pharmaceuticals’s Presence on LinkedIn
Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.
Cybersecurity Incidents Involving Hikma Pharmaceuticals
As of April 04, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.
Number of Peer and Competitor Companies
Hikma Pharmaceuticals has an estimated 5,608 peer or competitor companies worldwide.
Hikma Pharmaceuticals CyberSecurity History Information
How many cyber incidents has Hikma Pharmaceuticals faced ?
Total Incidents: According to Rankiteo, Hikma Pharmaceuticals has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at Hikma Pharmaceuticals ?
Incident Types: The types of cybersecurity incidents that have occurred include .
Incident Details
What are the most common types of attacks the company has faced ?
Additional Questions
.png)
Latest Global CVEs (Not Company-Specific)
Description
nimiq/core-rs-albatross is a Rust implementation of the Nimiq Proof-of-Stake protocol based on the Albatross consensus algorithm. Prior to version 1.3.0, two peer-facing consensus request handlers assume that the history index is always available and call blockchain.history_store.history_index().unwrap() directly. That assumption is false by construction. HistoryStoreProxy::history_index() explicitly returns None for the valid HistoryStoreProxy::WithoutIndex state. when a full node is syncing or otherwise running without the history index, a remote peer can send RequestTransactionsProof or RequestTransactionReceiptsByAddress and trigger an Option::unwrap() panic on the request path. This issue has been patched in version 1.3.0.
Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
Description
PraisonAI is a multi-agent teams system. Prior to version 1.5.95, FileTools.download_file() in praisonaiagents validates the destination path but performs no validation on the url parameter, passing it directly to httpx.stream() with follow_redirects=True. An attacker who controls the URL can reach any host accessible from the server including cloud metadata services and internal network services. This issue has been patched in version 1.5.95.
Risk Information
cvss3
Base: 8.6
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N
Description
PraisonAI is a multi-agent teams system. Prior to version 4.5.97, OAuthManager.validate_token() returns True for any token not found in its internal store, which is empty by default. Any HTTP request to the MCP server with an arbitrary Bearer token is treated as authenticated, granting full access to all registered tools and agent capabilities. This issue has been patched in version 4.5.97.
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description
PraisonAI is a multi-agent teams system. Prior to version 4.5.97, the PraisonAI Gateway server accepts WebSocket connections at /ws and serves agent topology at /info with no authentication. Any network client can connect, enumerate registered agents, and send arbitrary messages to agents and their tool sets. This issue has been patched in version 4.5.97.
Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description
PraisonAI is a multi-agent teams system. Prior to version 4.5.90, MCPToolIndex.search_tools() compiles a caller-supplied string directly as a Python regular expression with no validation, sanitization, or timeout. A crafted regex causes catastrophic backtracking in the re engine, blocking the Python thread for hundreds of seconds and causing a complete service outage. This issue has been patched in version 4.5.90.
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
Access Data Using Our API
Get company history
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=hikma-pharmaceuticals' -H 'apikey: YOUR_API_KEY_HERE'
RapidWhat Do We Measure ?
Incident
Finding
Grade
Digital Assets
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Network Security
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
SBOM (Software Bill of Materials)
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
CMDB (Configuration Management Database)
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Threat Intelligence
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
